www.fdanews.com/articles/87811-toyama-launches-rheumatoid-arthritis-trials
TOYAMA LAUNCHES RHEUMATOID ARTHRITIS TRIALS
June 23, 2006
Japan-based Toyama Chemical has begun Phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis (RA).
A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.
The development of the drug has been sponsored by the Japan Science and Technology Agency, the company said.